Compare
Aptevo Therapeutics Inc. vs Skye Bioscience, Inc. vs Biofrontera Inc. vs Neuphoria Therapeutics Inc.
| Latest fiscal year | Aptevo Therapeutics Inc. APVORevenue covers only part of its income (partial revenue) | Skye Bioscience, Inc. SKYE | Biofrontera Inc. BFRI | Neuphoria Therapeutics Inc. NEUP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | n/a | $41.70M | $1.17M |
| Revenue growth (YoY) | n/a | n/a | +11.7% | -92.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -27.2% | n/m |
| Net margin | n/a | n/a | -25.3% | n/m |
| Net income | -$25.97M | -$55.92M | -$10.54M | -$13.45M |
| EPS (Diluted) | -$87.27 | -$1.41 | -$1.04 | -$3.06 |
| Operating cash flow | -$25.59M | -$43.06M | -$13.36M | -$12.35M |
| Free cash flow | n/a | -$43.07M | -$13.36M | n/a |
| Cash & equivalents | $21.62M | $5.88M | $6.39M | $19.87M |
| Total assets | $27.19M | $28.31M | $28.56M | $28.71M |
| Total liabilities | $9.81M | $8.29M | $18.08M | $4.11M |
| Shareholders' equity | $17.38M | $20.02M | $10.48M | $24.60M |
| Return on year-end equity | -149.4% | -279.3% | -100.5% | -54.7% |
| Shares outstanding | 997.8K | 33.38M | 11.65M | 5.41M |
Revenue, most recent five fiscal years
| Fiscal year | Aptevo Therapeutics Inc. | Skye Bioscience, Inc. | Biofrontera Inc. | Neuphoria Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $41.70M Ended 2025-12-31 | $1.17M Ended 2026-06-30 |
| 1 year earlier | n/a | n/a | $37.32M Ended 2024-12-31 | $15.65M Ended 2025-06-30 |
| 2 years earlier | n/a | n/a | $34.07M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $28.67M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $24.10M Ended 2021-12-31 | n/a |